tracking

A Once-in-a-Lifetime Opportunity in Healthcare Is Here

Healthcare is going through a major transition phase and is ripe for innovation, that much we know for sure. We also know that innovation comes from talented leadership, backed by smart investors.

iSelect is working with industry experts to accelerate this transition, partnering with leading medical professionals and institution to help make promising healthcare innovations a reality. Our approach is based around the simple idea that true change in health and medicine is going to come from the inside, from the doctors, researchers, and other healthcare professionals who are doing this work every day.

We want to partner with them. We want to support their ideas. We want to help their companies grow.

We work with major research centers to find the most promising opportunities, and we work with doctors to match our diligence and deal sourcing with their medical expertise to back the select few companies with the most promise. So far, this includes companies focused on chronic pain, cancer, epilepsy, pulmonary fibrosis and more.

They are the experts in healthcare. iSelect is the expert in venture investing. Together we can solve this problem.

Join our healthcare market network.

Selection Team

Bryce Rutter

Bryce Rutter

B2B Technology Team, Healthcare Team

Dr. Rutter is founder and CEO of Metaphase Design Group, a design firm serving industrial, commercial and consumer product and packaging clients internationally.  He is an acknowledged specialist in ergonomic product design and a leading worldwide expe …

Read full bio >

Michael Nichols

Michael Nichols

B2B Technology Team, Healthcare Team

Michael Nichols, Ph.D. presently serves as an investor and C level management for various startups. He serves as an Analyst for Vinlogx, a platform that acquires, stores, and analyses internal vehicle information enabling solutions across multiple auto …

Read full bio >

Chas Eggert

Chas Eggert

Agriculture Team, Healthcare Team, Resource Efficiency Team

Charles R. (Chas) Eggert has 40 years of experience in the specialty chemicals industry with a proven track record of creating value for startups and large global businesses. Chas is an operating partner focused on specialty chemical investments with A …

Read full bio >

David Christenson

David Christenson



Healthcare Team

David Christenson joined BioGenerator as an Entrepreneur-in-Residence in 2015 focusing primarily on healthcare and specifically in information technology, care delivery and payment, and services. Over a 30-year career, David has developed substantive b …

Read full bio >

Michael Beat

Michael Beat

Healthcare Team

Presently leading Arch Cancer Care as Medical Director, Dr. Beat is a local expert in collaborative prostate cancer management. At a national level, he contributes to physician leadership committees within the US Oncology Network. Having earned an exec …

Read full bio >

Bobby Sandage

Bobby Sandage

Healthcare Team

Bobby Sandage is currently President and CEO of Euclises, Chairman of the board of Immunophotonics, member of the board of directors of EDIS, a member of the Cultivation Capital life sciences fund investment committee and am a member of the Selection C …

Read full bio >

Melissa Walker

Melissa Walker

Healthcare Team

A regulatory professional with over 27 years of experience in the medical products industry, Melissa currently serves as Founder, President and CTO at Graematter, Inc. and Senior VP Regulatory at Topera. Specialties include regulatory intelligence rese …

Read full bio >

Renaldo Cataldo

Dr. Renato Cataldo

B2B Technology Team, Healthcare Team

An accomplished senior executive with start-ups, growth, and turn-around organizations, Renato developed a healthcare technology corporation, HealthTech Solutions, from a small start-up of 3 people to a national provider of technical solutions to healt …

Read full bio >

iSelect Companies

Gila is developing a treatment for obesity using naturally occurring hormones (PYY) known to induce satiety, leading to weight loss. Gila is developing formulations to be applied to the tongue prior to meals, which have successfully induced satiety in animal testing without causing the nausea like symptoms associated with injectable and other formulations. For more information, see http://www.gilatherapeutics.com.
Learn more…

Entac Medical is developing noninvasive devices for predictive and diagnostic medicine based on a novel, patented, platform technology, Previs Audio Spectral Analysis Technology (PASAT). The first application, PrevisEA, is a noninvasive, disposable, self-contained device that is clinically proven to predict postoperative ileus (POI) in surgical patients.
Learn more…

Zumbro Discovery is a biotech company developing novel peptides for the treatment of resistant hypertension (RH), a condition characterized by a combination of cardiovascular, kidney and adrenal gland complications. RH is an indication with no approved drugs that affects 12% of US hypertensives, or 9 million Americans, and an estimated 300 million people worldwide.
Learn more…

Cofactor Genomics uses proprietary RNA sequencing technology and machine learning algorithms to diagnose disease. RNA serves as a real-time barometer of a person’s health, as opposed to DNA which remains little changed throughout a person’s life and whose analysis is estimated to diagnose less than 5% of diseases. Compared to current methods, Cofactor’s patent pending RNA isolation technology allows the Company to detect specific RNA molecules from low-quality tissue samples, making 100x more patient specimens available for analysis.
Learn more…

Indalo Therapeutics (formerly known as Antegrin Therapeutics, Inc.), based in St. Louis, MO is a biopharmaceutical company developing and testing novel compounds that inhibit the development of pulmonary (lung) fibrosis and other fibrotic diseases by inhibiting proteins that are the key drivers of the fibrotic process. Uncontrolled, fibrosis can cause diseased organs to stop functioning.
Learn more…

Euclises Pharmaceuticals is developing and testing novel cyclooxygenase-2 (COX-2, an enzyme responsible for inflammation and pain) inhibitors designed to increase the anti-cancer potency and effectiveness of chemotherapy safely, offering new treatment options for patients suffering from colorectal, non-small cell lung and pancreatic cancers. For more information, see http://www.euclises.com.
Learn more…

Neuros Medical, Inc., a Cleveland, Ohio based neuromodulation company, is focused on developing proprietary therapies for unmet needs to patients worldwide. The company’s patented platform technology, Altius® Electrical Nerve Block, is focused on elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.
Learn more…

Tansna Therapeutics, Inc., based in St. Louis, MO, is developing and testing anticonvulsant drugs for the treatment of epilepsy. Worldwide, at least 50 million people suffer from epilepsy, 30% of whom are unable to achieve adequate seizure control using existing medications. Tansna’s proprietary anticonvulsant compounds have been shown in animal testing to prevent seizures in such otherwise therapy-resistant patients. For more information, see http://www.tansna.com.
Learn more…

Read More from iSelect

Register to Learn More